Soleno Therapeutics Stock Price, News & Analysis (NASDAQ:SLNO) $28.94 -0.89 (-2.98%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$28.28▼$30.5350-Day Range$20.67▼$29.8352-Week Range$0.85▼$30.53Volume389,262 shsAverage Volume394,074 shsMarket Capitalization$882.67 millionP/E RatioN/ADividend YieldN/APrice Target$38.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Soleno Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside31.3% Upside$38.00 Price TargetShort InterestHealthy3.33% of Float Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment-0.13Based on 8 Articles This WeekInsider TradingAcquiring Shares$15.12 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.43) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.58 out of 5 starsMedical Sector122nd out of 952 stocksElectromedical Equipment Industry2nd out of 21 stocks 3.5 Analyst's Opinion Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.00, Soleno Therapeutics has a forecasted upside of 31.3% from its current price of $28.94.Amount of Analyst CoverageSoleno Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.33% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soleno Therapeutics has recently decreased by 15.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSoleno Therapeutics has received a 73.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Soleno Therapeutics is -0.55. Previous Next 1.0 News and Social Media Coverage News SentimentSoleno Therapeutics has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Soleno Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 12 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have bought 727.65% more of their company's stock than they have sold. Specifically, they have bought $15,115,340.00 in company stock and sold $1,826,287.00 in company stock.Percentage Held by Insiders28.80% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Soleno Therapeutics are expected to grow in the coming year, from ($2.43) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 22.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Soleno Therapeutics Stock (NASDAQ:SLNO)Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Read More SLNO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLNO Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CFO James H. Mackaness Sells 4,186 Shares of StockDecember 5, 2023 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 27,716 Shares of StockDecember 5, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 3, 2023 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Sells $696,387.36 in StockDecember 3, 2023 | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Sets New 52-Week High at $30.42December 1, 2023 | finance.yahoo.comInsider Sell Alert: CFO James Mackaness Sells 8,081 Shares of Soleno Therapeutics Inc (SLNO)November 28, 2023 | finance.yahoo.com3 Biotech Stocks With Big-Time Breakthrough PotentialNovember 26, 2023 | seekingalpha.comSoleno Therapeutics: Impressive Data, But Never Forget AmarinDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 21, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Soleno TherapeuticsNovember 10, 2023 | markets.businessinsider.comUndervalued Potential: Soleno Therapeutics’ Promising Prospects and Upward Price Target RevisionNovember 7, 2023 | morningstar.comSoleno Therapeutics Inc SLNONovember 7, 2023 | finance.yahoo.comSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 3, 2023 | msn.comSoleno Therapeutics (SLNO) Price Target Increased by 14.43% to 37.74October 16, 2023 | finance.yahoo.comThe Ten Most-Shorted Stocks Include Huge Market Movers In 2023October 6, 2023 | finance.yahoo.comXerox, Mastercraft Boat, and More Stocks See Action From Activist InvestorsOctober 5, 2023 | msn.comSoleno Therapeutics (SLNO) Price Target Increased by 162.16% to 32.98October 4, 2023 | finance.yahoo.comSoleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research SymposiumOctober 4, 2023 | finance.yahoo.comCorrecting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research SymposiumOctober 3, 2023 | msn.comMeet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505%October 2, 2023 | finance.yahoo.comSoleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional SharesSeptember 29, 2023 | msn.comSoleno Therapeutics' 10% owner buys $15M worth of stockSeptember 27, 2023 | finance.yahoo.comSoleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded WarrantsSeptember 27, 2023 | finance.yahoo.comWhy Shares of Soleno Therapeutics Dropped on WednesdaySeptember 27, 2023 | finance.yahoo.comSoleno Therapeutics Stock Dives After Its Meteoric Rise on Positive Study ResultsSeptember 27, 2023 | finance.yahoo.comIndividual investors in Soleno Therapeutics, Inc. (NASDAQ:SLNO) are its biggest bettors, and their bets paid off as stock gained 494% last weekSeptember 27, 2023 | finance.yahoo.comSoleno (SLNO) Soars as Prader-Willi Syndrome Study Meets GoalSee More Headlines Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLNO CUSIPN/A CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees25Year FoundedN/APrice Target and Rating Average Stock Price Target$38.00 High Stock Price Target$40.00 Low Stock Price Target$35.00 Potential Upside/Downside+31.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-272.89% Return on Assets-94.44% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book22.79Miscellaneous Outstanding Shares30,500,000Free Float21,715,000Market Cap$882.67 million OptionableNot Optionable Beta-1.39 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Anish Bhatnagar M.D. (Age 53)President, CEO, COO & Director Comp: $835.2kMr. James H. MacKaness (Age 59)Chief Financial Officer Comp: $539kMs. Patricia C. Hirano (Age 57)Vice President of Regulatory Affairs Comp: $423.8kDr. Neil M. Cowen M.B.A.Ph.D., Senior Vice President of Drug DevelopmentMs. Kristen Yen M.S. (Age 54)Vice President of Clinical Operations Comp: $317.19kKey CompetitorsBioLife SolutionsNASDAQ:BLFSZynexNASDAQ:ZYXIAxoGenNASDAQ:AXGNSemler ScientificNASDAQ:SMLROutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsBhatnagar AnishSold 27,716 sharesTotal: $794,063.40 ($28.65/share)James H MackanessSold 4,186 sharesTotal: $119,928.90 ($28.65/share)Kristen YenSold 3,979 sharesTotal: $110,735.57 ($27.83/share)Bhatnagar AnishSold 25,678 sharesTotal: $696,387.36 ($27.12/share)James H MackanessSold 3,878 sharesTotal: $105,171.36 ($27.12/share)View All Insider TransactionsView All Institutional Transactions SLNO Stock Analysis - Frequently Asked Questions Should I buy or sell Soleno Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SLNO shares. View SLNO analyst ratings or view top-rated stocks. What is Soleno Therapeutics' stock price target for 2024? 3 equities research analysts have issued 12-month target prices for Soleno Therapeutics' shares. Their SLNO share price targets range from $35.00 to $40.00. On average, they anticipate the company's share price to reach $38.00 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts. How have SLNO shares performed in 2023? Soleno Therapeutics' stock was trading at $1.98 at the start of the year. Since then, SLNO stock has increased by 1,361.6% and is now trading at $28.94. View the best growth stocks for 2023 here. When is Soleno Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024. View our SLNO earnings forecast. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its earnings results on Tuesday, November, 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.33. When did Soleno Therapeutics' stock split? Soleno Therapeutics shares reverse split before market open on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD). Who are Soleno Therapeutics' major shareholders? Soleno Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (32.06%), Carlyle Group Inc. (22.96%), Adage Capital Partners GP L.L.C. (13.28%), RA Capital Management L.P. (12.40%), Silverarc Capital Management LLC (3.70%) and Emerald Advisers LLC (2.49%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SLNO) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.